Ejaz Ahmad Khera | Materials Simulation | Best Researcher Award

Dr. Ejaz Ahmad Khera | Materials Simulation | Best Researcher Award


Dr. Ejaz Ahmad Khera is an Assistant Professor of Physics at The Islamia University of Bahawalpur, Pakistan, and an HEC-approved supervisor with a PhD in the characterization of materials for memory storage and neuromorphic applications using DFT. He has published over 30 high-impact international research articles and currently leads research at the Materials Modeling and Simulation Lab, where he supervises MPhil and PhD students. His group is actively involved in developing efficient double perovskites for solar cell applications. In addition to his academic and research roles, Dr. Khera contributes to departmental administrative functions and has participated in multiple international conferences in physics and materials science. He is proficient in VASP, Wien2k, CASTEP, and other computational tools, reflecting his strong background in computational materials physics.

Profile

Education 🎓

Dr. Khera earned his PhD in Physics from The Islamia University of Bahawalpur (2016–2021), focusing on DFT-based characterization of materials for neuromorphic and memory applications. He holds an MPhil in Physics from Allama Iqbal Open University, Islamabad (2012–2014), and a Master of Science in Physics from Bahauddin Zakariya University, Multan (2007–2010). His academic foundation combines theoretical physics, computational modeling, and practical understanding of solid-state and condensed matter systems. He is trained in multiple simulation platforms including VASP, Wein2k, and CASTEP, and has built expertise in data analysis software like Origin and visualization tools like VESTA and Crystal Maker. His solid academic training has enabled him to mentor graduate students in computational material science and renewable energy research domains. Dr. Khera has also enhanced his academic exposure through participation in pedagogical and research methodology training programs.

Experience 👨‍🏫

Dr. Khera is currently serving as Assistant Professor of Physics at The Islamia University of Bahawalpur since March 2022, where he teaches undergraduate and postgraduate courses, leads research, and manages academic administration. From 2019 to 2021, he was a visiting lecturer at University of Education, Multan Campus, and previously taught physics at Admire Group of Colleges (2017–2021), Muslim Group of Colleges (2013–2017), and Educators Group of Colleges (2011–2013), focusing on undergraduate and higher secondary education. Over a decade of teaching experience has honed his expertise in delivering core physics concepts and mentoring students. In his academic tenure, Dr. Khera has also built research collaborations and guided MPhil and PhD students in materials modeling. His responsibilities have included curriculum design, academic planning, and seminar coordination. He is deeply engaged in academic development through active participation in physics conferences and workshops.

Awards & Recognitions 🏅

Dr. Khera received the Prime Minister Youth Laptop Scheme award from the Federal Government of Pakistan in 2018, recognizing his academic excellence and contribution to higher education. He was also granted the Punjab Government Scholarship under the Fee Reimbursement Scheme for Higher Education in 2017, awarded by the Government of Punjab. These honors reflect his academic merit, commitment to research, and service in the field of physics education. He has participated in multiple international and national-level conferences, including events hosted by The Islamia University of Bahawalpur and The Women University Multan. His consistent performance in academics and his role in teaching and research supervision have earned him institutional recognition. Additionally, his HEC-approved supervisor status further signifies his qualification and leadership in guiding advanced research projects in Pakistan. These accolades support his active involvement in national education development and scientific advancement in materials science.

Research Interests 🔬

Dr. Khera’s research is centered on computational materials science with a focus on density functional theory (DFT)-based investigations of electronic, optical, thermoelectric, and structural properties of novel materials. His primary interest lies in characterizing double perovskites (DPs), Heusler alloys, and vacancy-ordered compounds for use in solar cells, memory storage, brain-inspired neuromorphic systems, and energy harvesting applications. Using simulation tools like VASP, CASTEP, and Wien2k, he studies materials such as Ga₂PtX₆, Li₂ATlCl₆, and Na₂PtX₆ for their optoelectronic and thermoelectric performance. His recent publications explore halogen modification, spin polarization, and hybrid perovskites for sustainable technologies. His research group actively contributes to discovering lead-free, high-efficiency materials that align with global goals for clean and renewable energy. Dr. Khera also collaborates internationally, co-authoring papers with scientists across Asia and Europe, thereby advancing the field of computational physics and sustainable material development.

Publications

 

  • Probing the opto-electronic, thermoelectric, thermodynamic and elastic responses
    of lead-free double perovskite Li2ATlCl6 (A= Na and K) for potential photovoltaic
    and high-energy applications: A DFT study
    Reference: Qiguo Xiao, Abrar Nazir, Ejaz Ahmad Khera, Mumtaz Manzoor, Ramesh
    Sharma, Javed Rahman, Sabah Ansar, Farooq Ali
    Link: https://www.sciencedirect.com/science/article/pii/S0921510724006895

 

  • First principles investigation of structural, electronic, optical, transport properties
    of double perovskites X2TaTbO6 (X= Ca, Sr, Ba) for optoelectronic and energy
    harvesting applications
    Reference: Mudassir Ishfaq, Muniba Urooj, Muhammad Sajid, Khawar Ismail, Rimsha
    Baqeel, Ejaz Ahmad Khera, Rajwali Khan, Sattam Al Otaibi, Khaled Althubeiti, Hassan Ali,
    Ghulam Murtaza, Muhammad Jamil
    Link: https://www.sciencedirect.com/science/article/pii/S0022369724005675

 

 

Nathan Robert Wall | Medicine | Excellence in Research Award

Dr. Nathan Robert Wall | Medicine | Excellence in Research Award

Dr. Nathan R. Wall is an accomplished academic, biomedical researcher, and military officer. He is currently an Associate Professor of Medicine at Loma Linda University School of Medicine and holds multiple leadership roles in research, oncology education, and national defense. With advanced degrees in biology, cancer biology, and business administration, he has dedicated his career to cancer research and military medical operations. Dr. Wall has served in multiple deployments with the California Army National Guard, including missions in Afghanistan, Poland, and Iraq. His military and academic excellence is recognized through numerous awards and honors. Dr. Wall combines rigorous research in molecular medicine with a passion for leadership, education, and national service. His extensive experience in academia, clinical research, and military command uniquely positions him at the intersection of science and strategic operations, contributing to both medical advancement and national security.

Profile

Education 🎓

Dr. Nathan R. Wall is currently pursuing a Master of Strategic Studies at the U.S. Army War College (2024–2026). He earned his MBA with a focus in Management from the University of Redlands (2006–2008), and a Ph.D. in Cancer Biology from Wayne State University (1996–2000), where he also completed an M.S. in Molecular Biology and Genetics. Prior to that, he obtained an M.S. in Biology (1992–1995) and a B.S. in Biology with a minor in Chemistry (1987–1991) from Walla Walla College (now Walla Walla University). His graduate training included mentorship under leading scientists like Dr. Ayad M. Al-Katib and Dr. Joan M. Redd. Across disciplines—from molecular biology to strategic leadership—Dr. Wall’s education reflects a commitment to interdisciplinary excellence, equipping him with the skills to navigate both biomedical research and complex military operations with strategic insight.

Experience 👨‍🏫

Dr. Nathan R. Wall has held academic appointments at Loma Linda University since 2008, currently serving as Associate Professor of Medicine in the Division of Human Anatomy. He also directs Research and Development at the James M. Slater Proton Treatment & Research Center and is Oncology Thread Director at the School of Medicine. Previously, he served in the Department of Biochemistry and Center for Health Disparities. Since 2008, Dr. Wall has simultaneously served in the California Army National Guard, rising through the ranks and completing deployments to Afghanistan, Poland, and Iraq in key command roles. He has also contributed as a scientific advisor for biotech firms and participated in Department of Defense medical research review panels. His interdisciplinary experience spans military medicine, molecular oncology, academic leadership, and national defense, making him a unique leader who bridges science, strategy, and service.

Awards & Recognitions 🏅

Dr. Wall’s exemplary service has earned him numerous military and civilian accolades. These include the Bronze Star Medal, NATO Medal, Afghanistan Campaign Medal, Global War on Terrorism Service Medal, and the Honorable Order of Saint Martin. He’s received multiple Army Commendation and Achievement Medals, along with California-specific honors like the California Medal of Merit and Drill Attendance Ribbon with multiple stars. Notably, he was recognized as “Citizen Warrior of the Month” by California ARNG Magazine in August 2018. Dr. Wall has also been honored with plaques and certificates from NATO, Bulgarian Joint Forces, and various military medical programs. His academic achievements include tenure at Loma Linda University and leadership roles in key training inspections. These honors reflect his unwavering commitment to excellence, leadership in medical readiness, and profound impact in both academic and military sectors.

Research Interests 🔬

Dr. Wall’s research focuses on cancer biology, with specific expertise in molecular mechanisms of disease, targeted therapies, and translational oncology. His work bridges basic science and clinical application, especially in the context of proton therapy and health disparities in underserved populations. At Loma Linda University, he leads interdisciplinary teams addressing tumor microenvironments, cancer signaling pathways, and innovative therapeutics. Dr. Wall also contributes to Department of Defense research as a peer reviewer, ensuring scientific rigor in funded medical studies. His research often integrates his military background, exploring how stress and trauma-related factors influence cancer biology and immune responses. As Director of R&D at a leading proton treatment center, he’s advancing precision medicine in oncology. Dr. Wall’s work is marked by its practical implications, scientific depth, and commitment to improving patient care—particularly for populations affected by health inequities or involved in military service.

Publications
  • Seco-Duocarmycin SA in Aggressive Glioblastoma Cell Lines

    International Journal of Molecular Sciences
    2025-03-19 | Journal article
    CONTRIBUTORS: Ann Morcos; Yeonkyu Jung; Ryan N. Fuller; Antonella Bertucci; Amy Nguyen; Quanqing Zhang; Tobias Emge; Kristopher E. Boyle; Nathan R. Wall; Marcelo Vazquez
  • A Comprehensive Review of the Antitumor Properties and Mechanistic Insights of Duocarmycin Analogs

    Cancers
    2024-09-27 | Journal article
    CONTRIBUTORS: Ann Morcos; Yeonkyu Jung; Joab Galvan Bustillos; Ryan N. Fuller; David Caba Molina; Antonella Bertucci; Kristopher E. Boyle; Marcelo E. Vazquez; Nathan R. Wal
  • A CTB-SARS-CoV-2-ACE-2 RBD Mucosal Vaccine Protects Against Coronavirus Infection

    Vaccines
    2023-12-18 | Journal article
    CONTRIBUTORS: Béla Dénes; Ryan Fuller; Wayne Kelin; Tessa Levin; Jaipuneet Gil; Aaren Harewood; Márta Lőrincz; Nathan Wall; Anthony Firek; William Langridg

Natalia Baran | Cancer Research | Best Researcher Award

Assist. Prof. Dr. Natalia Baran | Cancer Research | Best Researcher Award

Leading Attending at InselSpital Bern, Switzerland.

Dr. Natalia Baran is an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center, where she focuses on developing novel therapeutic strategies targeting metabolic vulnerabilities in leukemia. Her expertise lies in understanding how metabolic reprogramming can lead to drug resistance and contribute to leukemia progression. With a medical background and extensive experience in both clinical and research settings, Dr. Baran has been at the forefront of studies that aim to modulate metabolic pathways to enhance anti-leukemic responses. By combining insights from molecular biology, immunology, and clinical practice, she is actively working toward discovering innovative treatments for leukemia. Dr. Baran’s research holds great promise in advancing leukemia therapy, particularly by targeting metabolic reprogramming in the context of therapy resistance. Her multidisciplinary approach, integrating clinical data with laboratory research, makes her a key figure in leukemia research.

Profile

Scopus

Google Scholar

Orcid

Education:

Dr. Natalia Baran completed her undergraduate studies in Biotechnology, earning a Master of Science degree in 2006 from Wroclaw University of Science and Technology in Poland. She further pursued medical education and obtained her Medical Doctor (MD) degree from Wroclaw Medical University in 2007. Driven by her passion for research, Dr. Baran earned a Ph.D. in Medicine from the University of Bonn in 2015. Her doctoral research laid the foundation for her current focus on leukemia and metabolic reprogramming. In addition, Dr. Baran underwent extensive postdoctoral training at MD Anderson Cancer Center, where she honed her expertise in hematology and oncology, contributing significantly to translational research in leukemia. Her diverse educational background, blending science and medicine, has shaped her comprehensive approach to cancer research.

Professional Experience:

Dr. Baran has a rich professional experience that bridges clinical practice and cutting-edge research. After completing her MD, she pursued clinical residencies in Internal Medicine, Hematology, and Oncology at prestigious German institutions, including the University of Heidelberg and the University of Bonn. This clinical experience laid the groundwork for her subsequent focus on leukemia research. In 2016, she joined MD Anderson Cancer Center as a Postdoctoral Fellow in the Department of Leukemia. During her postdoctoral tenure, Dr. Baran worked closely with Dr. Marina Konopleva, exploring the role of metabolic pathways in leukemia resistance. By 2022, she had transitioned to an Assistant Professor role, continuing her translational research in leukemia, with a particular emphasis on identifying novel therapeutic strategies. Her clinical and research experiences synergize to enhance her contributions to the leukemia research community.

Research Interests:

Dr. Baran’s research is primarily centered on exploring metabolic vulnerabilities and their role in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Her work seeks to understand the mechanisms through which metabolic reprogramming in leukemia cells contributes to drug resistance and tumor progression. Dr. Baran is particularly interested in how modulating the metabolic environment can enhance the effectiveness of leukemia therapies. By focusing on the interplay between metabolism and leukemic cell survival, she aims to identify new therapeutic strategies that target metabolic pathways to overcome resistance to traditional treatments. Her research also explores how immune modulation can be integrated with metabolic interventions to develop more efficient leukemia therapies.

Awards and Honors:

Dr. Baran has received recognition for her contributions to leukemia research, although specific awards are not detailed in available sources. However, her research has been featured prominently in major scientific forums, including the Annual Metabolism in Cancer Symposium organized by MD Anderson. Her work has earned her respect within the scientific community, as evidenced by her continued role as an Assistant Professor and her involvement in prestigious cancer research initiatives. Dr. Baran’s impact is evident in her ongoing efforts to bridge the gap between basic science and clinical application, aiming to revolutionize leukemia treatment.

Skills:

Dr. Baran’s research skills encompass a wide range of techniques in molecular biology, cell culture, and metabolic analysis. She is highly proficient in studying the metabolic pathways that drive leukemia, using state-of-the-art technologies such as high-resolution metabolic flux analysis, RNA sequencing, and advanced cell imaging. Dr. Baran is skilled at integrating basic science with clinical data, ensuring that her research translates into practical therapeutic interventions. Her expertise in immunology further complements her research in leukemia, allowing her to investigate the potential of combining metabolic therapies with immune modulation to improve patient outcomes. Her interdisciplinary approach is a key strength in her ongoing work in leukemia research.

Publication Top Notes

A Selective BCL-XL PROTAC Degrader Achieves Safe and Potent Antitumor Activity

  • Authors: S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, et al.
  • Journal: Nature Medicine
  • Volume: 25(12), Pages 1938–1947
  • Cited by: 515
  • Year: 2019

Targeting a Cytokine Checkpoint Enhances the Fitness of Armored Cord Blood CAR-NK Cells

  • Authors: M Daher, R Basar, E Gokdemir, N Baran, N Uprety, AK Nunez Cortes, et al.
  • Journal: Blood, The Journal of the American Society of Hematology
  • Volume: 137(5), Pages 624–636
  • Cited by: 226
  • Year: 2021

Inhibiting Glutaminase in Acute Myeloid Leukemia: Metabolic Dependency of Selected AML Subtypes

  • Authors: P Matre, J Velez, R Jacamo, Y Qi, X Su, T Cai, SM Chan, A Lodi, et al.
  • Journal: Oncotarget
  • Volume: 7(48), Pages 79722
  • Cited by: 194
  • Year: 2016

Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials

  • Authors: TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, et al.
  • Journal: Nature Medicine
  • Volume: 29(1), Pages 115–126
  • Cited by: 182
  • Year: 2023

Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy

  • Authors: N Baran, M Konopleva
  • Journal: Clinical Cancer Research
  • Volume: 23(10), Pages 2382–2390
  • Cited by: 126
  • Year: 2017

Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-Like Responses Against CD30+ Malignancies

  • Authors: LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, et al.
  • Journal: Clinical Cancer Research
  • Volume: 27(13), Pages 3744–3756
  • Cited by: 117
  • Year: 2021

Clonal Selection and Therapy Resistance in Acute Leukemias: Mathematical Modelling Explains Different Proliferation Patterns at Diagnosis and Relapse

  • Authors: T Stiehl, N Baran, AD Ho, A Marciniak-Czochra
  • Journal: Journal of The Royal Society Interface
  • Volume: 11(94), Article ID 20140079
  • Cited by: 106
  • Year: 2014

Activation of RAS/MAPK Pathway Confers MCL-1 Mediated Acquired Resistance to BCL-2 Inhibitor Venetoclax in Acute Myeloid Leukemia

  • Authors: Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, et al.
  • Journal: Signal Transduction and Targeted Therapy
  • Volume: 7(1), Article ID 51
  • Cited by: 104
  • Year: 2022

Conclusion:

Dr. Natalia Baran is a prominent researcher whose work in leukemia has the potential to transform therapeutic approaches, especially through targeting metabolic pathways. Her strong academic background, combined with extensive clinical and research experience, enables her to address one of the most pressing challenges in leukemia treatment: drug resistance. By focusing on metabolic reprogramming, Dr. Baran is paving the way for innovative strategies to combat leukemia and improve patient outcomes. Her expertise in integrating basic research with clinical applications ensures that her contributions will have a lasting impact on the field of oncology, particularly in the development of new, more effective therapies for leukemia.